Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) has granted marketing authorization for DUPIXENT®(dupilumab), for use in adults with moderate-to-severe atopic dermatitis (AD) who are candidates for systemic therapy.

This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.

Existing Users Log In
   
Forgot password? Click here to reset
New User Registration
 
 
 
 
 
 
Please indicate that you agree to the Terms of Service *
*Required field